PressSeptember 21, 2022 Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
PressSeptember 21, 2022 Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
PressSeptember 21, 2022 COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
PressSeptember 20, 2022 Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board
PressSeptember 20, 2022 MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
PressSeptember 20, 2022 Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy
PressSeptember 19, 2022 Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency
PressSeptember 19, 2022 Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder
PressSeptember 19, 2022 PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted
PressSeptember 19, 2022 Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
PressSeptember 19, 2022 Braxia Scientific Announces Court Approval of Class Action Settlement in Canada
PressSeptember 19, 2022 Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants
PressSeptember 19, 2022 Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™
PressSeptember 16, 2022 PharmaTher Announces Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine
PressSeptember 16, 2022 Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
